ARCT
$13.96
Arcturus Therapeutics
($1.11)
(7.37%)
ARCT
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus:  ($1.94)
Revenue:  $7.54 Mil
Tuesday
Nov 8
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ARCT reports earnings?
Beat
Meet
Miss

Where is ARCT's stock price going from here?
Up
Flat
Down
Stock chart of ARCT
Analysts
Summary of analysts' recommendations for ARCT
Score
Grade
Pivots
Resistance
$16.99
$16.12
$15.60

$14.73

Support
$14.21
$13.34
$12.82
Tweet
Growth
Description
Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA.